Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760

Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein

Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577

Induced protein degradation: an emerging drug discovery paradigm

Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486

Catalytic in vivo protein knockdown by small-molecule PROTACs

Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140

The dTAG system for immediate and target-specific protein degradation

Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118

Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality

Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065

Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery

Xi, J., Zhang, R., Chen, K., Yao, L., Li, M., Jiang, R., Li, X., & Fan, L. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105848 · Cited by 45

Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)

Wang, H., Zhou, R., Xu, F., Yang, K., Zheng, L., Zhao, P., Shi, G., Dai, L., Xu, C., Yu, L., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00385-8 · Cited by 48

Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer’s disease model mice

Yao, D., Li, T., Yu, L., Hu, M., He, Y., Zhang, R., Wu, J., Li, S., Kuang, W., Yang, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1351792 · Cited by 46

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications

Reyes-Garau, D., Ribeiro, M. L., & Roué, G. (2019) · Cancers · doi:10.3390/cancers11101483 · Cited by 45

The application of PROTAC in HDAC

Chen, S., Zheng, Y., Liang, B., Yin, Y., Yao, J., Wang, Q., Liu, Y., & Neamati, N. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115746 · Cited by 45

Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR WT and EGFR T790M

Aboelez, M. O., Belal, A., Xiang, G., & Ma, X. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2062338 · Cited by 42

Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies

Pradeepkiran, J. A., & Reddy, P. H. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166162 · Cited by 41

Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase

Rana, S., Mallareddy, J. R., Singh, S., Boghean, L., & Natarajan, A. (2021) · Cancers · doi:10.3390/cancers13215506 · Cited by 43

Recent advances in targeted protein degraders as potential therapeutic agents

Yang, N., Kong, B., Zhu, Z., Huang, F., Zhang, L., Lu, T., Chen, Y., Zhang, Y., & Jiang, Y. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10606-w · Cited by 44

Native Mass Spectrometry for the Study of PROTAC GNE‐987‐Containing Ternary Complexes

Sternicki, L. M., Nonomiya, J., Liu, M., Mulvihill, M. M., & Quinn, R. J. (2021) · ChemMedChem · doi:10.1002/cmdc.202100113 · Cited by 40

Overcoming TRAIL Resistance for Glioblastoma Treatment

Deng, L., Zhai, X., Liang, P., & Cui, H. (2021) · Biomolecules · doi:10.3390/biom11040572 · Cited by 40

PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs

Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38

Is PROTAC technology really a game changer for central nervous system drug discovery?

Farrell, K., & Jarome, T. J. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1915979 · Cited by 39

Towards design of drugs and delivery systems with the Martini coarse-grained model

Kjølbye, L. R., Pereira, G. P., Bartocci, A., Pannuzzo, M., Albani, S., Marchetto, A., Jiménez‐García, B., Martin, J., Rossetti, G., Cecchini, M., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16 · Cited by 42

WWP1 E3 ligase at the crossroads of health and disease

Behera, A., & Reddy, A. B. M. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06380-0 · Cited by 38

DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras

Li, F., Hu, Q., Zhou, Y., Yang, H., & Bai, F. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae358 · Cited by 39

Synthesis of 7-benzylguanosine cap-analogue conjugates for eIF4E targeted degradation

Kaur, T., Menon, A., & Garner, A. L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.080 · Cited by 38

PROTAC: targeted drug strategy. Principles and limitations

Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 38

A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders

Fischer, P. D., Papadopoulos, E., Dempersmier, J. M., Wang, Z., Nowak, R. P., Donovan, K. A., Kalabathula, J., Gorgulla, C., Junghanns, P., Kabha, E., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113435 · Cited by 37

PROTACs for BRDs proteins in cancer therapy: a review

Wang, C., Zhang, Y., Yang, S., Chen, W., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2081164 · Cited by 37

PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras

Madan, J., Ahuja, V. K., Dua, K., Samajdar, S., Ramchandra, M., & Giri, S. (2022) · BioDrugs · doi:10.1007/s40259-022-00551-9 · Cited by 37

Cell-Permeable PROTAC Degraders against KEAP1 Efficiently Suppress Hepatic Stellate Cell Activation through the Antioxidant and Anti-Inflammatory Pathway

Wang, F., Zhan, Y., Li, M., Wang, L., Zheng, A., Liu, C.-B., Wang, H., & Wang, T. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00165 · Cited by 36

Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations

Vartak, R., Deore, B., Sanhueza, C., & Patel, K. R. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126413 · Cited by 37

PROTACable Is an Integrative Computational Pipeline of 3-D Modeling and Deep Learning To Automate the De Novo Design of PROTACs

Mslati, H., Gentile, F., Pandey, M. K., Ban, F., & Cherkasov, A. R. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01878 · Cited by 37

Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy

Zhang, D., Ma, B., Liu, D., Wu, W., Zhou, T., Gao, Y., Yang, C., Jian, Y., Fan, Y., Qian, Y., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105212 · Cited by 34

Targeting the SAGA and ATAC Transcriptional Coactivator Complexes in MYC-Driven Cancers

Mustachio, L. M., Roszik, J., Farria, A. T., & Dent, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3652 · Cited by 35

MCM10 compensates for Myc‐induced DNA replication stress in breast cancer stem‐like cells

Murayama, T., Takeuchi, Y., Yamawaki, K., Natsume, T., Li, M., Marcela, R. N., Nishimura, T., Kogure, Y., Nakata, A., Tominaga, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14776 · Cited by 34

The Advent of Molecular Targeted Therapies Against Cancer. Toward Multi‐Targeting Drugs Through Materials Engineering: A Possible Future Scenario

Puzzo, M., Santo, M. D., Morelli, C., Leggio, A., & Pasqua, L. (2024) · Small Science · doi:10.1002/smsc.202400113 · Cited by 37

Development and Utility of a PAK1-Selective Degrader

Chow, H.-Y., Karchugina, S., Groendyke, B. J., Toenjes, S. T., Hatcher, J. M., Donovan, K. A., Fischer, E. S., Abalakov, G., Faezov, B., Dunbrack, R. L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00756 · Cited by 31

Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review

Wang, C., Zhang, Y., Chen, W., Wang, Y., & Xing, D. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188927 · Cited by 34

Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides

Shiah, J. V., Grandis, J. R., & Johnson, D. E. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0599 · Cited by 32

PROTACs technology for targeting non-oncoproteins: Advances and perspectives

Wang, C., Zhang, Y., Xing, D., & Zhang, R. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105109 · Cited by 32

Construction of an IMiD-based azide library as a kit for PROTAC research

Liu, H., Sun, R., Ren, C., Qiu, X., Yang, X., & Jiang, B. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02120b · Cited by 30

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31

Polymer-based nanoparticles for chemo/gene-therapy: Evaluation its therapeutic efficacy and toxicity against colorectal carcinoma

Chen, Y., Li, N., Xu, B., Wu, M., Yan, X., Zhong, L., Cai, H., Wang, T., Wang, Q., Long, F., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109257 · Cited by 31

A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts

Chernobrovkin, A. L., Cázares-Körner, C., Friman, T., Caballero, I. M., Amadio, D., & Molina, D. M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220984372 · Cited by 28

BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade

Tong, J., Tan, X., Risnik, D., Gao, M., Song, X., Ermine, K., Shen, L., Wang, S., Yu, J., & Zhang, L. (2021) · Oncogene · doi:10.1038/s41388-021-02041-8 · Cited by 29

The role of DMPK science in improving pharmaceutical research and development efficiency

Mak, K., Epemolu, O., & Pichika, M. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.005 · Cited by 30

Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions

Vikal, A., Maurya, R., Patel, B. B., Sharma, R. K., Patel, P., Patil, U. K., & Kurmi, B. D. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01754-z · Cited by 29

In silico Druggability Assessment of the NUDIX Hydrolase Protein Family as a Workflow for Target Prioritization

Michel, M., Homan, E. J., Wiita, E., Pedersen, K., Almlöf, I., Gustavsson, A., Lundbäck, T., Helleday, T., & Berglund, U. W. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00443 · Cited by 28

The application of ubiquitin ligases in the PROTAC drug design

Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 29

Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs

Kou, P., Levy, E. S., Nguyen, A. D., Zhang, D., Chen, S., Cui, Y., Zhang, X., Broccatelli, F., Pizzano, J., Cantley, J. L., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082098 · Cited by 31

Central Nervous System Targeted Protein Degraders

Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023) · Biomolecules · doi:10.3390/biom13081164 · Cited by 30

TACkling Cancer by Targeting Selective Protein Degradation

Noblejas‐López, M. D. M., Tébar-García, D., López‐Rosa, R., Alcaraz-Sanabria, A. L., Cristóbal‐Cueto, P., Pinedo‐Serrano, A., Rivas‐García, L., & Galán‐Moya, E. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102442 · Cited by 29

PROTAC delivery in tumor immunotherapy: Where are we and where are we going?

Li, Y., Wu, Y., Gao, S., Sun, T., & Jiang, C. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.076 · Cited by 29

E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression

Sinha, A., Iyengar, P. V., & ten Dijke, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020476 · Cited by 30

Selective degradation-inducing probes for studying cereblon (CRBN) biology

Powell, C. E., Du, G., Bushman, J. W., He, Z., Zhang, T., Fischer, E. S., & Gray, N. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00382d · Cited by 29

Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs

Muddassir, M., Soni, K. V., Sangani, C. B., AlArifi, A. S., Afzal, M. F., Abduh, N. A. Y., Duan, Y., & Bhadja, P. (2020) · RSC Advances · doi:10.1039/d0ra07971e · Cited by 27

Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs

Huang, J., Fu, X., Qiu, F., Liang, Z., Cao, C., Wang, Z., Chen, H., Yue, S., Xie, D., Liang, Y., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14650 · Cited by 27

Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation

Lin, J., Chen, Z., Zhang, D., Zhang, N., Chen, H., & Guo, D. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202401051 · Cited by 28

Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress

Chen, J., Feng, D., Zhu, R., Li, H., & Chen, L. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103781 · Cited by 29

Peptide-based PROTACs: Current Challenges and Future Perspectives

Wang, H., Chen, M., Zhang, X., Xie, S., Qin, J., & Li, J. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230130121822 · Cited by 28

Strategies to Investigate Ubiquitination in Huntington's Disease

Sap, K. A., & Reits, E. A. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00485 · Cited by 25

Monobodies as tool biologics for accelerating target validation and druggable site discovery

Akkapeddi, P., Teng, K. W., & Koide, S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00188d · Cited by 24

Advances in the Design and Development of PROTAC-mediated HDAC Degradation

Rodrigues, D. A., Roe, A. J., Griffith, D. M., & Chonghaile, T. N. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211015092047 · Cited by 27

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer

Pacini, L., Jenks, A. D., Vyse, S., Wilding, C. P., Arthur, A., & Huang, P. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s242045 · Cited by 27

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications

Thapa, R., Bhat, A. A., Gupta, G., Jyothi, S. R., Kaur, I., Kumar, S., Sharma, N., Prasad, G. V. S., Pramanik, A., & Ali, H. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70009 · Cited by 26

Targeted degradation of CD147 proteins in melanoma

Zhou, Z., Long, J., Wang, Y., Li, Y., Zhang, X., Tang, L. Y., Chang, Q., Chen, Z., Hu, G., Hu, S., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104453 · Cited by 26

Are we ready to design oral PROTACs®?

Jiménez, D. G., Sebastiano, M. R., Caron, G., & Ermondi, G. (2021) · ADMET & DMPK · doi:10.5599/admet.1037 · Cited by 24

Targeted protein degradation in antibacterial drug discovery?

Gopal, P., & Dick, T. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.11.005 · Cited by 24

Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?

Severini, L. L., Bufalieri, F., Infante, P., & Marcotullio, L. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.854352 · Cited by 23

Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein

Ohoka, N., Suzuki, M., Uchida, T., Tsuji, G., Tsukumo, Y., Yoshida, M., Inoué, T., Demizu, Y., Ohki, H., & Naito, M. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00402 · Cited by 23

Developments of PROTACs technology in immune-related diseases

Wang, C., Zhang, Y., Deng, J., Liang, B., & Xing, D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115127 · Cited by 23

Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer’s Disease

Bhatia, S., Singh, M., Singh, T., & Singh, V. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03722-w · Cited by 22

SPOP-mutant prostate cancer: Translating fundamental biology into patient care

Bernasocchi, T., & Theurillat, J.-P. P. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.024 · Cited by 22

Targeting phosphatases: From molecule design to clinical trials

Guo, M., Li, Z., Gu, M., Gu, J., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116031 · Cited by 23

Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy

Groppe, J. C. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1660641 · Cited by 22

Degradation of intracellular TGF-β1 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events

Feng, Y., Su, H., Li, Y., Luo, C., Xu, H., Wang, Y., Sun, H., Wan, G., Zhou, B., & Bu, X. (2020) · Chemical Communications · doi:10.1039/c9cc08391j · Cited by 22

Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells

Massafra, V., Tundo, S., Dietzig, A., Ducret, A., Jöst, C., Klein, C., Kontermann, R. E., Knoetgen, H., Steegmaier, M., Romagnani, A., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000252 · Cited by 23

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

Wang, C., Zhang, Y., Zhang, T., Shi, L., Geng, Z., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2076675 · Cited by 22

Targeted protein degradation using the lysosomal pathway

Ghosh, S., Ramadas, B., & Manna, D. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00273f · Cited by 22

High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules

Tian, Y., Seifermann, M., Bauer, L., Luchena, C., Wiedmann, J. J., Schmidt, S., Geisel, A., Afonin, S., Höpfner, J., Brehm, M., et al. (2024) · Small · doi:10.1002/smll.202307215 · Cited by 20

Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms

Faryal, B., Abideen, Z. U., Irfan, M., Ahmed, H., Jalilov, F. S., Abduraximova, L., & Ashraf, G. A. (2026) · Biomolecules · doi:10.3390/biom16020325 · Cited by 24

Exploring PROTAC Cooperativity with Coarse-Grained Alchemical Methods

Mai, H., Zimmer, M. H., & Miller, T. F. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c05795 · Cited by 22

Computational strategies for PROTAC drug discovery

Wu, J., Wang, W., & Leung, C. (2023) · Acta Materia Medica · doi:10.15212/amm-2022-0041 · Cited by 22

AQP4 Endocytosis-Lysosome Degradation Mediated by MMP-9/β-DG Involved in Diabetes Cognitive Impairment

Yuan, Y., Peng, W. J., Lei, J., Zhao, Y., Zhao, B., Li, Y., Wang, J., & Qu, Q. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04085-9 · Cited by 20

Evaluating physiochemical properties of FDA-approved orally administered drugs

Reese, T. C., Devineni, A., Smith, T., Lalami, I., Ahn, J., & Raj, G. V. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2275617 · Cited by 20

Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation

Gross, P. H., Sheets, K. J., Warren, N. A., Ghosh, S., Varghese, R. E., Wass, K. E., & Kadimisetty, K. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.048 · Cited by 19

Hydrogen Peroxide‐Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

Yu, D., Fan, H., Zhou, Z., Zhang, Y., Sun, J., Wang, L., Jia, Y., Tian, J., Campbell, A., Mi, W., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300422 · Cited by 21

Advanced proteomics approaches to unravel protein homeostasis

Grandi, P., & Bantscheff, M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.02.001 · Cited by 19

A small molecular multi-targeting tyrosine kinase inhibitor, anlotinib, inhibits pathological ocular neovascularization

Lu, C., Zhang, Q., Zhang, H., Li, X., Jiang, Q. L., & Yao, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111493 · Cited by 19

A System for the Evolution of Protein–Protein Interaction Inducers

Dewey, J. A., Azizi, S., Lu, V., & Dickinson, B. C. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00276 · Cited by 19

Inhibition and interactions of alpha-amylase by daucosterol from the peel of Chinese water chestnut ( Eleocharis dulcis )

Gu, Y., Yang, X., Shang, C., Thao, T. T. P., & Koyama, T. (2021) · Food & Function · doi:10.1039/d1fo00887k · Cited by 19

Targeted protein modification as a paradigm shift in drug discovery

Amirian, R., Azadi Badrbani, M., Izadi, Z., Samadian, H., Bahrami, G., Sarvari, S., Abdolmaleki, S., Nabavi, S. M., Derakhshankhah, H., & Jaymand, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115765 · Cited by 18

Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge

Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169050 · Cited by 19

EGFR inhibitors across generations: Progress, challenges, and future directions

Deshmukh, V. G., Sapkal, S. B., Gadekar, S. S., & Deshmukh, V. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142326 · Cited by 20

Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In Vivo

Luo, T., Zheng, Q., Shao, L., Ma, T., Mao, L., & Wang, M. (2022) · Angewandte Chemie · doi:10.1002/ange.202206277 · Cited by 18

ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas

Jiang, B., Weinstock, D. M., Donovan, K. A., Sun, H.-W., Wolfe, A., Amaka, S., Donaldson, N. L., Wu, G., Jiang, Y. Z., Wilcox, R. A., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.03.007 · Cited by 19

Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection

Tian, L., Qiang, T., Yang, X., Yue, G., Zhai, X., Kang, K., Du, C., Lu, Q., Gao, H., Zhang, D., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115979 · Cited by 19

Decreasing acute toxicity and suppressing colorectal carcinoma using Sorafenib-loaded nanoparticles

Li, N., Chen, Y., Sun, H., Huang, T., Chen, T., Jiang, Y., Yang, Q., Yan, X., & Wu, M. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1718704 · Cited by 18

Exploring chemical space for “druglike” small molecules in the age of AI

Kattuparambil, A. A., Chaurasia, D. K., Shekhar, S., Srinivasan, A., Mondal, S., Aduri, R., & Jayaram, B. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1553667 · Cited by 19

Characterization of cereblon-dependent targeted protein degrader by visualizing the spatiotemporal ternary complex formation in cells

Kaji, T., Koga, H., Kuroha, M., Akimoto, T., & Hayata, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-59966-5 · Cited by 16

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17

Recent advances of PROTACs technology in neurodegenerative diseases

Wang, C., Zhang, Y., Yang, S., & Xing, D. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105015 · Cited by 17

Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B

Wilms, G., Schofield, K., Maddern, S., Foley, C., Shaw, Y., Smith, B. E., Basantes, L. E., Schwandt, K., Babendreyer, A., Chavez, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01130 · Cited by 19

Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1

Melnyk, J. E., Steri, V., Nguyen, H. G., Hwang, Y. C., Gordan, J. D., Hann, B. C., Feng, F. Y.-C., & Shokat, K. M. (2022) · Oncogene · doi:10.1038/s41388-022-02179-z · Cited by 16

Targeting Histone Lysine Demethylase LSD1/KDM1A as a New Avenue for Cancer Therapy

Fang, Y., Liao, G., & Yu, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/156802661911190725094910 · Cited by 17

Multifunctional Small Molecules as Potential Anti-Alzheimer’s Disease Agents

Bargagna, B., Ciccone, L., Nencetti, S., Santos, M. A., Chaves, S., Camodeca, C., & Orlandini, E. (2021) · Molecules · doi:10.3390/molecules26196015 · Cited by 16

Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment

Huang, L. H., Shao, J., Lai, W., Gu, H., Yang, J., Shi, S., Wufoyrwoth, S., Song, Z., Zou, Y., Xu, Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116159 · Cited by 16

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells

Arbel, Y. S., Katz, B., Gabizon, R., Shraga, A., Bronstein, Y., Kamdjou, T., Levin, A. G., Perry, C., Avivi, I. M., London, N., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.646971 · Cited by 16

Recent Advances in Small Molecule PROTACs for the Treatment of Cancer

Li, W., Elhassan, R. M., Hou, X., & Fang, H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666201117141611 · Cited by 22

Small-molecule PROTACs: Novel Agents for Cancer Therapy

Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 32

Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery

Pei, H., Peng, Y., Zhao, Q., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra03423d · Cited by 70

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

He, M., Lv, W., & Rao, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.685106 · Cited by 63

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 57